Global oncology imaging Imaging Endpoints is the largest global imaging CRO in oncology with offices across North America, Europe, and Asia, presenting a broad market reach for partnerships, expansion of trials, and cross-border studies.

Regulatory excellence A perfect inspection record and zero observations across FDA, EMEA and other major regulators highlight a strong quality track record, which can be leveraged to upsell risk-managed engagements and premium CRO services.

AI and radiomics Recent initiatives to develop radiomics-ready workflows and an AI-compatible research framework signal an opportunity to cross-sell advanced imaging analytics, data management, and regulatory-compliant AI submissions to pharma sponsors pursuing precision oncology.

Strategic leadership New leadership in global marketing and a stable executive team combined with deep science expertise and a robust publication footprint can be used to position IE as a trusted partner for large, high-profile Phase 3 trials and outsourced imaging strategy.

Affiliations and scale Affiliations with HonorHealth and major radiology groups, plus 15 years of sustained growth and low turnover, provide credibility for expanding to additional sites, ongoing sponsor engagements, and multinational trial charters.